Our data suggested that SXT could suppress the activation of IKKβ/NF-κB signal pathway in liver and decrease the CRP, TNF-α, IL-6, and IL-1β levels in serum of T2DM rats, which were corresponding with the results that insulin resistance was markedly ameliorated in SXT-treated diabetes rats. This evidence concerns the gene IL1B and type 2 diabetes mellitus.